Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study
Background COVID-19 associated mucormycosis (CAM) has been known as one of the most severe post-COVID morbidities. Objectives To describe CAM cases, identify possible risk factors, and report outcomes of patients. Methods This retrospective study was performed in Amir-Alam Hospital, Tehran, Iran between February 2020 and September 2021. Patients with mucormycosis who had an active or previous diagnosis of COVID-19 have been included. Results Of 94 patients with mucormycosis, 52 (33 men and 19 women; mean age: 57.0 ± 11.82 years) were identified with an active or history of COVID-19. Rhino-orbital, rhino maxillary, rhino-orbito cerebral subtypes of mucormycosis were detected in 6 (11.5%), 18(34.6%), and 28(53.8%) patients. As a control group, 130 (69 men and 61 women; mean age: 53.10 ± 14.49 years) random RT-PCR-confirmed COVID-19 patients without mucormycosis have been included. The mean interval between COVID-19 diagnosis and initial mucormycosis symptoms was 16.63 ± 8.4 days (range 0–51). Those in the CAM group had a significantly more severe course of COVID-19 (OR = 3.60, P-value < 0.01). Known history of previous diabetes mellitus (OR = 7.37, P-value < 0.01), smoking (OR = 4.55, P-value < 0.01), and history of receiving high-dose corticosteroid pulse therapy because of more severe COVID-19 (P-value = 0.022) were found as risk factors. New-onset post-COVID hyperglycemia was lower in the CAM group (46.2% vs. 63.8%; OR = 0.485, P-value = 0.028). After treatment of the CAM group, 41(78.8%) of patients recovered from mucormycosis. The mean ages of the expired patients in the CAM group were significantly higher than those who recovered from mucormycosis (66.18 ± 9.56 vs. 54.56 ± 11.22 years; P < 0.01); and COVID-19 disease was more severe (P = 0.046). Conclusion Either active or history of COVID-19 can cause an increase in the risk of mucormycosis development. Some of the most important risk factors are the medical history of diabetes mellitus, smoking, and high-dose corticosteroid therapy. CAM is important possible comorbidity related to COVID-19, which could make the post-COVID conditions more complicated. More research and studies with greater sample sizes among different ethnicities are needed to explore the association between COVID-19 and mucormycosis..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:187 |
|---|---|
| Enthalten in: |
Mycopathologia - 187(2022), 5-6 vom: 06. Okt., Seite 469-479 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tavakolpour, Soheil [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© Crown 2022 |
|---|
| doi: |
10.1007/s11046-022-00670-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2080019260 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2080019260 | ||
| 003 | DE-627 | ||
| 005 | 20230511085518.0 | ||
| 007 | tu | ||
| 008 | 230131s2022 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11046-022-00670-5 |2 doi | |
| 035 | |a (DE-627)OLC2080019260 | ||
| 035 | |a (DE-He213)s11046-022-00670-5-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 580 |a 570 |q VZ |
| 084 | |a 12 |2 ssgn | ||
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a 42.00 |2 bkl | ||
| 100 | 1 | |a Tavakolpour, Soheil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Crown 2022 | ||
| 520 | |a Background COVID-19 associated mucormycosis (CAM) has been known as one of the most severe post-COVID morbidities. Objectives To describe CAM cases, identify possible risk factors, and report outcomes of patients. Methods This retrospective study was performed in Amir-Alam Hospital, Tehran, Iran between February 2020 and September 2021. Patients with mucormycosis who had an active or previous diagnosis of COVID-19 have been included. Results Of 94 patients with mucormycosis, 52 (33 men and 19 women; mean age: 57.0 ± 11.82 years) were identified with an active or history of COVID-19. Rhino-orbital, rhino maxillary, rhino-orbito cerebral subtypes of mucormycosis were detected in 6 (11.5%), 18(34.6%), and 28(53.8%) patients. As a control group, 130 (69 men and 61 women; mean age: 53.10 ± 14.49 years) random RT-PCR-confirmed COVID-19 patients without mucormycosis have been included. The mean interval between COVID-19 diagnosis and initial mucormycosis symptoms was 16.63 ± 8.4 days (range 0–51). Those in the CAM group had a significantly more severe course of COVID-19 (OR = 3.60, P-value < 0.01). Known history of previous diabetes mellitus (OR = 7.37, P-value < 0.01), smoking (OR = 4.55, P-value < 0.01), and history of receiving high-dose corticosteroid pulse therapy because of more severe COVID-19 (P-value = 0.022) were found as risk factors. New-onset post-COVID hyperglycemia was lower in the CAM group (46.2% vs. 63.8%; OR = 0.485, P-value = 0.028). After treatment of the CAM group, 41(78.8%) of patients recovered from mucormycosis. The mean ages of the expired patients in the CAM group were significantly higher than those who recovered from mucormycosis (66.18 ± 9.56 vs. 54.56 ± 11.22 years; P < 0.01); and COVID-19 disease was more severe (P = 0.046). Conclusion Either active or history of COVID-19 can cause an increase in the risk of mucormycosis development. Some of the most important risk factors are the medical history of diabetes mellitus, smoking, and high-dose corticosteroid therapy. CAM is important possible comorbidity related to COVID-19, which could make the post-COVID conditions more complicated. More research and studies with greater sample sizes among different ethnicities are needed to explore the association between COVID-19 and mucormycosis. | ||
| 650 | 4 | |a Mucormycosis | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a CAM | |
| 700 | 1 | |a Irani, Shirin |4 aut | |
| 700 | 1 | |a Yekaninejad, Mir Saeed |4 aut | |
| 700 | 1 | |a Alimardi, Masoud |4 aut | |
| 700 | 1 | |a Hasibi, Mehrdad |4 aut | |
| 700 | 1 | |a Abdollahi, Hamed |4 aut | |
| 700 | 1 | |a Kazemi, Mohammad Ali |4 aut | |
| 700 | 1 | |a Lotfi, Maryam |4 aut | |
| 700 | 1 | |a Shahbazian, Haneyeh |4 aut | |
| 700 | 1 | |a Nazemian Yazdi, Nader Ali |4 aut | |
| 700 | 1 | |a Samimiardestani, Seyedhadi |4 aut | |
| 700 | 1 | |a Firouzifar, Mohammadreza |4 aut | |
| 700 | 1 | |a Farahbakhsh, Farbod |4 aut | |
| 700 | 1 | |a Mirzaee Goodarzi, Mohammadreza |4 aut | |
| 700 | 1 | |a Feiz, Firoozeh |4 aut | |
| 700 | 1 | |a Salehinia, Farahnaz |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Mycopathologia |d Springer Netherlands, 1938 |g 187(2022), 5-6 vom: 06. Okt., Seite 469-479 |w (DE-627)12993738X |w (DE-600)391081-7 |w (DE-576)015498093 |x 0369-299X |7 nnns |
| 773 | 1 | 8 | |g volume:187 |g year:2022 |g number:5-6 |g day:06 |g month:10 |g pages:469-479 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s11046-022-00670-5 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-FOR | ||
| 912 | |a GBV_ILN_252 | ||
| 936 | b | k | |a 42.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 187 |j 2022 |e 5-6 |b 06 |c 10 |h 469-479 | ||